mdm2 N-terminal domain bound to a p53 peptide

1/2 the digital resolution error stated in ppm/pt.

Journal of the American Chemical Society
Analysis of chemical shift changes reveals the binding modes of isoindolinone inhibitors of the MDM2-p53 interaction.

residues 12-16 correspond to the remnant of a GST-tag

Crystal Structure Of Human Mdm2 With An Imidazoline Inhibitor

Structure Of Human Mdm2 In Complex With A Benzodiazepine Inhibitor

Structure Of Human Mdm2 In Complex With An Optimized P53 Peptide

Mdm2 Bound To The Transactivation Domain Of P53

Mdm2 In Complex With An 8-Mer P53 Peptide Analogue

Solution Structure Of Hdm2 With Engineered Cyclotide

Crystal Structure Of Human Mdm2 In Complex With A 12-Mer Peptide Inhibitor

Structure Of Human Mdm2 In Complex With High Affinity Peptide

Crystal Structure Of Human Mdm2 In Complex With A Potent Miniature Protein Inhibitor (18-Residues)

Crystal Structure Of Human Mdm2 Complexed With D-peptide (12 Residues)

Crystal Structure Of Mdm2 With Chromenotriazolopyrimidine 1

Human Mdm2 Liganded With A 12mer Peptide Inhibitor (Pdi6w)

Human Mdm2 Liganded With A 12mer Peptide Inhibitor (Pdiq)

Structure Of Human Mdm2 Protein In Complex With A Small Molecule Inhibitor

Structure Of Human Mdm2 Protein In Complex With Mi-63-Analog

Crystal Structure Of Human Mdm2 In Complex With D-Peptide Inhibitor (Dpmi-Alpha)

Crystal Structure Of Human Mdm2 With A 12-Mer Peptide Inhibitor Pmi (N8a Mutant)

Structure Of A Novel Submicromolar Mdm2 Inhibitor

Crystal Structure Of Human Mdm2 In Complex With A Trifluoromethylated D-peptide Inhibitor

Exhaustive Fluorine Scanning Towards Potent P53-Mdm2 Antagonist

Structure Of The Stapled P53 Peptide Bound To Mdm2

Structure Of Hdm2 With Dimer Inducing Indolyl Hydantoin Ro-2443

Crystal Structure Of Human Mdm2 With A Dihydroimidazothiazole Inhibitor

The Central Valine Concept Provides An Entry In A New Class Of Non Peptide Inhibitors Of The P53-Mdm2 Interaction

Crystal Structure Of Mdm2 (17-111) In Complex With Compound 23

Crystal Structure Of Mdm2 (17-111) In Complex With Compound 29 (Am- 8553)

Crystal Structure Of An Mdm2/p53 Peptide Complex

Crystal Structure Of An Mdm2/nutlin-3a Complex

Co-crystal Structure Of Mdm2 With Inhibitor (2s,5r,6s)-2-benzyl-5,6- Bis(4-bromophenyl)-4-methylmorpholin-3-one

Co-crystal Structure Of Mdm2 With Inhibitor (2s,5r,6s)-2-benzyl-5,6- Bis(4-chlorophenyl)-4-methylmorpholin-3-one

Co-crystal Structure Of Mdm2 With Inhibitor (2r,3e)-2-[(2s,3r,6s)-2,3- Bis(4-chlorophenyl)-6-(4-fluorobenzyl)-5-oxomorpholin-4-

Co-crystal Structure Of Mdm2 With Inhibitor (2's,3r,4's,5'r)-n-(2- Aminoethyl)-6-chloro-4'-(3-chloro-2-fluorophenyl)-2'-(2,2- D

Co-crystal Structure Of Mdm2 With Inhibitor {(2s,5r,6s)-6-(3- Chlorophenyl)-5-(4-chlorophenyl)-4-[(2s)-1-hydroxybutan-2-yl]-3-

Co-crystal Structure Of Mdm2 (17-111) In Complex With Compound 25

Co-crystal Structure Of Mdm2 With Inhibitor Compound 4

Co-crystal Structure Of Mdm2(17-111) In Complex With Compound 48

Co-crystal Structure Of Mdm2 With Inhibitor Compound 49

Tetra-substituted Imidazoles As A New Class Of Inhibitors Of The P53- Mdm2 Interaction

Co-crystal Structure Of Mdm2 (17-111) With Compound 16, {(3r,5r,6s)-5- (3-chlorophenyl)-6-(4-chlorophenyl)-1-[(1s)-1-(6-cyclopr

Crystal Structure Of Compound 16 Bound To Mdm2(17-111), {(3r,5r,6s)-5- (3-chlorophenyl)-6-(4-chlorophenyl)-1-[(1s)-1-cyclopropy

Discovery Of Dihydroisoquinolinone Derivatives As Novel Inhibitors Of The P53-mdm2 Interaction With A Distinct Binding Mode: Hd

Discovery Of Nvp-cgm097 - A Highly Potent And Selective Mdm2 Inhibitor Undergoing Phase 1 Clinical Trials In P53wt Tumors: Hdm2

PREDICTED: E3 ubiquitin-protein ligase Mdm2 isoform X2 [Homo sapiens]

PREDICTED: E3 ubiquitin-protein ligase Mdm2 isoform X2 [Mustela putorius furo]

GST-tagged, 3C precision protease cleavable

1H, 15N, C-alpha and C-beta assignments of human MDM2 residues 17-125

a GE/Oxford instruments magnet fitted with a bruker cryogenic probe and console.

prepared as GST-fusion in a 3-step purification procedure comprising affinity chromatography, 3C precision protease cleavage and a final gel filtration step.

Delaglio, Grzesiek, Vuister, Zhu, Pfeifer and Bax